3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
210
Triple Negative Breast Neoplasms
32
Stomach Neoplasms
30
Inflammatory Breast Neoplasms
21
Esophageal Neoplasms
15
Carcinoma, Hepatocellular
15
Lymphoma, Large B-Cell, Diffuse
9
Sarcoma
8
Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
6
Urinary Bladder Neoplasms
5
Breast Neoplasms, Male
5
Adenocarcinoma Of Esophagus
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Liver Neoplasms
4
Testicular Neoplasms
3
Primary Breast Cancer
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pathologic Complete Response
3
Hemangiosarcoma
3
Carcinoma, Ductal, Breast
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Recurrence
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplastic Cells, Circulating
2
Neoplasms, Germ Cell and Embryonal
2
Interventions
palbociclib
1
exemestane
1
Vinorelbine
1
Therapeutics
1
Tamoxifen
1
Risk Assessment
1
Paclitaxel
1
Letrozole
1
Influenza Vaccines
1
Fulvestrant
1
Focus Groups
1
Epirubicin
1
Drug Therapy
1
Counseling
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Patient Acceptance of Health Care
×
Epirubicin
×
Clear all
NCT03355157
2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4
Completed
130 enrolled